Abiopharma

News list

PULSE BIOSCIENCES, INC. (PLSE)

SEC News
April 07, 2026, 12:59 UTC

(75% Positive) PULSE BIOSCIENCES, INC. (PLSE) Announces Enrollment Update for months Due to Patient Enrollment Issues, Safety Review, Efficacy Assessment

Full text

News bot April 7, 2026, 1 p.m.

📋 PULSE BIOSCIENCES, INC. (PLSE) - Clinical Trial Update

Filing Date: 2026-04-07

Accepted: 2026-04-07 08:59:37

Event Type: Clinical Trial Update

Event Details:

PULSE BIOSCIENCES, INC. (PLSE) Announces Clinical Trial Update PULSE BIOSCIENCES, INC. (PLSE) provided an update on its clinical development programs. Clinical Development Highlights:

Drug Program: months, Center
Diseases/Conditions: treating recurrent, Atrial Fibrillation U
Clinical Stage: Clinical Study, pivotal trial
Collaboration: Atrial Fibrillation U.S. IDE Enrollment

🔬 Clinical Development Pipeline (PULSE BIOSCIENCES, INC.):

Product	Type	Development Stage	Therapeutic Area	Source
ER-100 epigenetic therapy	GENETIC	Phase PHASE1	Open Angle Glaucoma (OAG)	ClinicalTrials.gov
CellFX nsPFA Cardiac Catheter System	DEVICE	Approved	Atrial Fibrillation Paroxysmal	ClinicalTrials.gov
AP601	DRUG	Phase PHASE1	Solid Tumours	ClinicalTrials.gov
nPulse Vybrance Percutaneous Electrode System	DEVICE	Approved	Thyroid Nodule	ClinicalTrials.gov
Oral Omeprazole	DRUG	Phase PHASE3	Type 1 Diabetes	ClinicalTrials.gov
Oral Cyclosporine and Oral Omeprazole	DRUG	Phase PHASE3	Type 1 Diabetes	ClinicalTrials.gov
Placebos	DRUG	Phase PHASE3	Type 1 Diabetes	ClinicalTrials.gov
Oral Cyclosporine and Oral Lansoprazole	DRUG	Phase PHASE3	Type 1 Diabetes	ClinicalTrials.gov
Candida albicans Skin Test Antigen	BIOLOGICAL	Phase PHASE2	Warts	ClinicalTrials.gov
CellFX Device	DEVICE	Approved	Warts	ClinicalTrials.gov
Nano-Pulse Stimulation Device	DEVICE	Approved	Skin Lesion	ClinicalTrials.gov
Cryosurgery Liquid Nitrogen Sprayer	DEVICE	Approved	Warts	ClinicalTrials.gov
CellFX System Device	DEVICE	Approved	Warts	ClinicalTrials.gov
Nano-Pulse Stimulation (NPS)	DEVICE	Approved	Lesion Skin	ClinicalTrials.gov
Study Product, THC Product, Placebo	BEHAVIORAL	Preclinical	Motivation	ClinicalTrials.gov
Intralesional Electrodesiccation	DEVICE	Approved	Skin Lesion	ClinicalTrials.gov
CellFX System	DEVICE	Approved	BCC - Basal Cell Carcinoma	ClinicalTrials.gov
CellFX® Percutaneous Electrode (PE) System	DEVICE	Approved	Thyroid Nodule (Benign)	ClinicalTrials.gov
CellFX nsPFA Endocardial Ablation Catheter System	DEVICE	Approved	Atrial Fibrillation Paroxysmal	ClinicalTrials.gov
CellFX® nsPFA™ Cardiac Surgery System	DEVICE	Approved	Atrial Fibrillation	ClinicalTrials.gov
CellFX nano-pFA 360 Endocardial Ablation Catheter System	DEVICE	Approved	Atrial Fibrillation Paroxysmal	ClinicalTrials.gov
Placebo	DRUG	Phase PHASE3	Common Warts (Verruca Vulgaris)	ClinicalTrials.gov
Candin, Intradermal Solution	DRUG	Phase PHASE3	Common Warts (Verruca Vulgaris)	ClinicalTrials.gov

💼 Business Developments:

No business developments data available.

Structured Data:

Company Name: PULSE BIOSCIENCES, INC.
Ticker Symbol: PLSE